3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
Cyclophosphamide
62
Rituximab
47
fludarabine
35
fludarabine phosphate
27
obinutuzumab
17
Mycophenolic Acid
16
ibrutinib
15
Whole-Body Irradiation
15
Lenalidomide
15
Specimen Handling
14
Prednisone
14
Etoposide
14
venetoclax
13
pirtobrutinib
13
Doxorubicin
13
pembrolizumab
12
Tacrolimus
12
Magnetic Resonance Spectroscopy
11
Granulocyte Colony-Stimulating Factor
11
Filgrastim
11
Biopsy
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
X-Rays
9
Bendamustine Hydrochloride
9
polatuzumab vedotin
8
glofitamab
8
acalabrutinib
8
Immunotherapy, Adoptive
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled